AUPH: Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for AUPH
Across the 15 sessions after earlier AUPH headlines, the stock closed higher 9 times and lower 5 times, with a median move of 3.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AUPH | SPY |
|---|---|---|---|
| Oct 30, 2026 | Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress | -3.3% | -1.8% |
| Aug 20, 2026 | Aurinia Settles Patent Litigation with Teva | +6.8% | -0.8% |
| Aug 6, 2026 | Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress | +6.2% | -0.2% |
| Jul 6, 2026 | Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis | -0.8% | +0.9% |
| Jun 4, 2026 | LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death | +4.5% | +0.4% |
| Jun 3, 2026 | TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC. | +1.8% | -0.7% |
Quantisnow market dataNASDAQ
AUPH
Aurinia Pharmaceuticals Inc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for AUPH
Full AUPH profile on Quantisnow Follow AUPH and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time